| 6.55 -0.1 (-1.5%) | 10-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.81 | 1-year : | 10.05 |
| Resists | First : | 7.55 | Second : | 8.6 |
| Pivot price | 6.97 |
|||
| Supports | First : | 5.83 | Second : | 4.85 |
| MAs | MA(5) : | 6.47 |
MA(20) : | 7.13 |
| MA(100) : | 7.26  |
MA(250) : | 13.9 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 34.1 |
D(3) : | 29.9 |
| RSI | RSI(14): 42.9 |
|||
| 52-week | High : | 34.4 | Low : | 0.99 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BDSX ] has closed above bottom band by 30.5%. Bollinger Bands are 4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7 - 7.05 | 7.05 - 7.09 |
| Low: | 6.26 - 6.3 | 6.3 - 6.33 |
| Close: | 6.49 - 6.56 | 6.56 - 6.62 |
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
Mon, 20 Oct 2025
Nov. 3: Biodesix to Report Financial Results After Close with 4:30 p.m. ET Webcast - Stock Titan
Mon, 20 Oct 2025
Biodesix to Report Third Quarter 2025 Financial Results on November 3, 2025 - Sahm
Sat, 11 Oct 2025
It's Down 30% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks - 富途牛牛
Wed, 08 Oct 2025
Biodesix, Inc. (NASDAQ:BDSX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Tue, 30 Sep 2025
Biodesix, Inc. (NASDAQ:BDSX) Short Interest Update - MarketBeat
Thu, 18 Sep 2025
It's Down 27% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 8 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 56.7 (%) |
| Held by Institutions | 24.3 (%) |
| Shares Short | 98 (K) |
| Shares Short P.Month | 298 (K) |
| EPS | -5.2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.15 |
| Profit Margin | -53.7 % |
| Operating Margin | -48.5 % |
| Return on Assets (ttm) | -20.9 % |
| Return on Equity (ttm) | -219.7 % |
| Qtrly Rev. Growth | 11.6 % |
| Gross Profit (p.s.) | 7.53 |
| Sales Per Share | 9.56 |
| EBITDA (p.s.) | -3.51 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -30 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | -1.26 |
| PEG Ratio | 0 |
| Price to Book value | 40.93 |
| Price to Sales | 0.68 |
| Price to Cash Flow | -1.76 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|